Back to search results
NCT04989309

Left and Right Hemisphere Contributions to Speech Perception

Enrolling by Invitation
NAAges 18+InterventionalBasic science
University of Connecticut
~26 participants
Updated 2025-06-15 on ClinicalTrials.gov
What's tested:Transcranial Magnetic Stimulation

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Categorization accuracy
Measured over Immediately following the stimulation pulses (within one second of the final pulse).
+2 more outcomes measured

Conditions

Neural Bases of Speech Perception

Explore related trials

Speech Perception

Where it's being run

1 sites across 1 states
Connecticut1

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Monolingual native speaker of English
No history of neurological impairments or disease
Free of speech and language disorders (per self-report, and confirmed by short language battery described by Fidler, Vance, \& Plante, 2011)
Pure-tone thresholds of 30 decibels or better in both ears (no worse than mild hearing loss), with no more than 15 dB between-ear difference.
Right-handed, as confirmed by Oldfield Handedness Inventory

Exclusion

Any condition where TMS would be contraindicated according to the most recent guidelines, including, but not limited to:
History of seizure or epilepsy
Metal in the skull
Use of legal or illicit drugs that can potentially reduce the threshold for seizure. As examples, we list some exclusionary drugs in each of the following categories. This is not an exhaustive list of the exclusionary drugs. We consult with faculty in the University of Connecticut College of Pharmacy to check for seizure risk with other drugs that participants report.
Antidepressants including Imipramine, amitriptyline, sertraline, venlafaxine, buproprion
Antipsychotics including Chlorpromazine, clozapine, haloperidol, aripiprazole
Antivirals including foscarnet, ganciclovir
Antiparasitics including chloroquine, mefloquine (antiparasitics)
Antibiotics including penicillin, ampicillin
Immunosuppressants including cyclosporin
Anticholinergenics
Antihistimines (including over-the-counter drugs like Claritin \& Benadryl)
Sympathomimetics (including Sudafed, Ritalin).
Illegal drugs such as methamphetamines, cocaine, MDMA, ketamine.
Diagnosis of a psychiatric disorder (per self-report)
Pregnancy

What this trial measures

  • Categorization accuracyImmediately following the stimulation pulses (within one second of the final pulse).

    Participants categorize items which vary along a perceptual continuum. Steepness of the categorization curve is extracted to estimate categorization accuracy.

  • Two-alternative forced choice accuracyImmediately following the stimulation pulses (within one second of the final pulse).

    Participants are given two options and asked to indicate which item they heard in the previous signal. Accuracy in making this decision is a primary outcome measure.

  • Two-alternative forced choice reaction timeImmediately following the stimulation pulses (within one second of the final pulse).

    Participants are given two options and asked to indicate which item they heard in the previous signal. Reaction time to make this decision is a primary outcome measure.